Best Biotech ETFs Gets a Lift From Merck’s Cubist Buy

Shares of biotechnology firm Cubist Pharmaceuticals (NasdaqGS: CBST) are up more than 35% Monday after Dow component Merck (NYSE: MRK) said it will buy the company for $102 per share, a deal that values Cubist at $9.5 billion. News of the deal lifted the First Trust NYSE Arca Biotechnology Index...